The expected Early Use Authorization from the Food and Drug Administration of the Pfizer/BioNTech COVID-19 Vaccine, and subsequent approval from the Centers for Disease Control and Prevention, raise many questions about the effectiveness of the vaccine in helping to slow the spread and who should and can get it and when.
In this segment of TriHealth’s Health Talk Live, Local 12’s Liz Bonis is joined by TriHealth Medical Director for Infectious Disease, Stephen Blatt, MD, who shares what information is known so far and addresses topics including:
- The effectiveness of the Pfizer vaccine, especially for certain high-risk populations
- Reports about allergic reactions for a small number of people in the UK, and what you should consider in deciding whether you will receive the vaccine if you have a history of allergic reactions
- The level of immunity from the vaccine versus that gained if you have recently recovered from COVID-19 and what that could mean for prioritizing who receives it
- What you might expect after receiving the vaccination and what to consider in making your decision about receiving it
- An update on COVID-19 numbers in our hospitals and how the staff is managing the current surge in cases
Have a question for future segments of Health Talk Live? You can share them with Liz via her Facebook page or email.